TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11206417
Drug: Insulin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (2 mU/kg/min)
Study: 11206417
Drug: Hyperglycaemia (5.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (5.6 mmol/l, 11.1 mmol/l, 16.7 mmol/l)
Study: 11206417
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Hyperglycaemia with somatostatin
Study: 9205656
Drug: Saliva Orthana
Normalized name: AS Saliva Orthana
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saliva Orthana (mucin-containing oral spray)
Study: 9205656
Drug: Placebo (mucin-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mucin-free spray)
Study: 8440931
Drug: D protein
Normalized name: Bird protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: D protein vaccine (500 micrograms)
Study: 8440931
Drug: D protein
Normalized name: Bird protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: D protein vaccine
Study: 28350401
Drug: Lipopolysaccharide (LPS)
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipopolysaccharide (LPS) pre-treatment
Study: 28350401
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) pre-treatment
Study: 26143536
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin treatment
Study: 22767151
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of TER
Study: 21148518
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP)
Study: 15344541
Drug: Lansoprazole (LPZ)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LPZ) 30 mg/day
Study: 15344541
Drug: Lansoprazole (LPZ)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LPZ) 15 mg/day
Study: 15344541
Drug: Famotidine (FAM)
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine (FAM) 40 mg/day
Study: 11002217
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI) with 5‐FU at 600 mg/m(2)/day for 2 consecutive days per week and oral UFT at 400 mg/day for 5‐7 days per week, repeated 10 times (Group A)
Study: 11002217
Drug: Oral UFT
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UFT at 400 mg/day for 6 months (Group B)
Study: 9021437
Drug: Oral fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenoterol 2.5 mg 3 times daily
Study: 7940144
Drug: Timolol 0.25%
Normalized name: Timolol 0.25% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.25% eyedrops (during treatment)
Study: 7940144
Drug: Timolol withdrawn
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol withdrawn (off treatment)
Study: 3064818
Drug: Fresh human
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh human milk or fortified human milk with protein intake of 2.1 to 3.3 g/kg/day
Study: 18318773
Drug: Udenafil 25
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 25 mg
Study: 18318773
Drug: Udenafil 300
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 300 mg
Study: 18318773
Drug: Udenafil 100
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 100 mg (multiple dose)
Study: 18318773
Drug: Udenafil 200
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 200 mg (multiple dose)
Study: 12830439
Drug: Short daily
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short daily hemodialysis (HD)
Study: 12830439
Drug: Conventional thrice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional thrice-weekly hemodialysis (HD)
Study: 8887197
Drug: Growth hormone-releasing
Normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Growth hormone-releasing factor (GRF), 1,000 mg/day, given in addition to follicle-stimulating hormone (FSH)
Study: 8887197
Drug: Follicle-stimulating hormone
Normalized name: Follicle-stimulating hormone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follicle-stimulating hormone (FSH) alone (control group)
Study: 8887197
Drug: Growth hormone-releasing
Normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Growth hormone-releasing factor (GRF) with FSH
Study: 1355943
Drug: Standard nonspecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nonspecific treatment
Study: 6148163
Drug: Thyroid stimulating
Normalized name: Thyroid stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid stimulating antibody (TSAb) determinations before and at the end of treatment
Study: 6148163
Drug: End-treatment TSAb
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-treatment TSAb levels greater than 350%
Study: 6148163
Drug: End-treatment TSAb
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-treatment TSAb levels less than 350% or negative
Study: 3789694
Drug: Interferon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (3 X 10(6) IU of alpha 2b interferon, administered by subcutaneous injection, three times weekly for 12 weeks)
Study: 3789694
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered by subcutaneous injection, three times weekly for 12 weeks)
Study: 28177728
Drug: Daily light
Normalized name: TITANIUM DIOXIDE 63 mg in 1 mL / ZINC OXIDE 41 mg in 1 mL TOPICAL LOTION [DAILY LIGHT GUARD DEFENSE FLUID BROAD SPECTRUM SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily light physical activity for a minimum of 30 minutes starting a maximum of 30 minutes after a meal for 12 weeks
Study: 16563900
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose infusion (1 L) prior to catheterization
Study: 16563900
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dextrose infusion)
Study: 11746615
Drug: tolcapone 100
Normalized name: tolcapone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone 100 mg t.i.d. (possible increase to 200 mg t.i.d.)
Study: 11746615
Drug: pergolide titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: pergolide titrated to a maximum dose of 5 mg/day (mean final dose 2.2 mg/day)
Study: 2442506
Drug: Nisoldipine (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10-40 mg daily)
Study: 2442506
Drug: Verapamil (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (40-80 mg three times daily)
Study: 2442506
Drug: Nifedipine (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (long-acting form, 20-80 mg daily)
Study: 31618099
Drug: PES-G (grandiose-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: PES-G (grandiose-based entitlement)
Study: 28315068
Drug: nab-paclitaxel 150
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 150 mg/m2 (nP150)
Study: 28315068
Drug: nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 125 mg/m2 (nP125)
Study: 28315068
Drug: paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 80 mg/m2 (P80)
Study: 18089850
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: 6 weeks of daily prednisone and weekly vinblastine followed by 18 weeks of daily 6‐mercaptopurine with vinblastine/prednisone pulses
Study: 18089850
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (intensified treatment)
Study: 16514225
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg of 25 microg/kg butorphanol in combination with 0.25% bupivacaine
Study: 16514225
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg of 0.25% bupivacaine
Study: 16514225
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg of 25 microg/kg butorphanol diluted in normal saline
Study: 10790348
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 20 ppm nitric oxide (NO)
Study: 12580112
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug treatment
Study: 3510014
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (2 g for eight doses)
Study: 3510014
Drug: Irrigation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation of uterus and peritoneum with 2 g of antibiotic
Study: 3510014
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravenous and irrigation
Study: 28703859
Drug: 19 or
Normalized name: pediatric multivitamin no.119 ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19 or 38 mg iron for 60 days
Study: 28703859
Drug: Iron pills
Normalized name: iron carbonyl Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron pills
Study: 23905375
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SFI) at 1.5 mL/kg (dissolved in 250 mL 5% glucose solution), administered intravenously once daily for 5 days before operation.
Study: 23905375
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (control group), equal dose to SFI group, administered 30 min before anesthesia induction.
Study: 21568982
Drug: i-gel (mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel (mild subgroup)
Study: 21568982
Drug: i-gel (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel (moderate subgroup)
Study: 19123002
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m² on a 21-day schedule (group A)
Study: 19123002
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m² on a 7-day schedule (group B)
Study: 16820373
Drug: Tranilast 100
Normalized name: tranilast 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast 100 mg, 3 times daily (T(+) group)
Study: 16820373
Drug: Tranilast treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast treatment vs Control
Study: 15585141
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (40 mg or 0.01 ml/kg, subcutaneous injection, every 12 hours)
Study: 11027423
Drug: 13-Cis retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-Cis retinoic acid at a dose of 0.75 mg/kg/day
Study: 8436775
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg oral calcium
Study: 29186389
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg orally twice daily for 10 days
Study: 26994634
Drug: Supportive medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive medications (any)
Study: 26994634
Drug: Non-opioid psychotropic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid psychotropic medications
Study: 15764959
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg weekly for 48 weeks) + vitamin D (400 IU daily) + calcium (1000 mg daily)
Study: 15764959
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (400 IU daily) + calcium (1000 mg daily)
Study: 7850589
Drug: Ritodrine hydrochloride
Normalized name: Ritodrine Hydrochloride
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritodrine hydrochloride 10 mg by mouth
Study: 7850589
Drug: Monitoring without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monitoring without treatment
Study: 11191179
Drug: Flumazenil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 0.5 mg
Study: 15456079
Drug: peginterferon alpha-2a
Normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alpha-2a 180 microg once weekly
Study: 15456079
Drug: peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alpha-2b 1.0 microg/kg once weekly
Study: 11373253
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of alcohol per day (as beer, red wine or spirits) for 6 weeks
Study: 9170763
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) including detailed explanation of obsessive thoughts, exposure, response prevention, cognitive restructuring, and relapse prevention.
Study: 8190534
Drug: High titer
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titer Edmonston-Zagreb measles vaccine
Study: 8190534
Drug: Medium titer
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium titer Edmonston-Zagreb measles vaccine
Study: 29189583
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training performed in different sessions (CT)
Study: 24763755
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids administered within 2 to 3 days of antibiotic therapy
Study: 24763755
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids administered after 4 or more days of antibiotic therapy
Study: 24763755
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids administered earlier in patients with non-Nocardia keratitis
Study: 24763755
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids administered earlier in patients with no topical antibiotic use before enrollment
Study: 20097461
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (RAS inhibitors [ACE inhibitors plus ARBs] plus high‐dose statin and spironolactone)
Study: 20097461
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (ACE inhibitors with low‐dose statin)
Study: 18247193
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA, 1000 mg)
Study: 18247193
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EPA and fluoxetine
Study: 8701396
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFA) 3 g daily
Study: 6430310
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (0.3 mg i.m. followed by 0.4 mg every 6 h for 3 days)
Study: 6430310
Drug: Intermittent morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent morphine (10 mg i.m.)
Study: 6430310
Drug: Intermittent morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent morphine
Study: 31204885
Drug: Male contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Male contraceptive pill willingness
Study: 17113190
Drug: Continuous etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous etanercept therapy (50 mg once weekly)
Study: 17113190
Drug: Interrupted etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Interrupted etanercept therapy (50 mg once weekly)
Study: 17113190
Drug: Interrupted etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Interrupted etanercept therapy
Study: 12009350
Drug: Depot GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depot GnRH agonist followed by 17beta-estradiol transdermal patches (100 to 300 microg for at least 12 days)
Study: 12009350
Drug: Endometrial preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial preparation starting on day 1 of menstrual cycle with 200 microg increasing to 300 microg after 7 days
Study: 3841228
Drug: Pirenzepine 10
Normalized name: pirenzepine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 10 mg
Study: 7609299
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pirenzepine 10 mg and famotidine 20 mg
Study: 326594
Drug: 0.05% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% betamethasone 17,21-dipropionate cream
Study: 30519776
Drug: Vibrotactile feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrotactile feedback using a 'balance' belt worn around the waist for 1 month in daily life.
Study: 22185726
Drug: Intravenous esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esmolol infusion
Study: 8464394
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms nocloprost (solved in 50 cc water)
Study: 24219814
Drug: Nebulized tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nebulized tobramycin 300 mg twice a day (TNS)
Study: 24219814
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin (IV)
Study: 21979491
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lactobacillus rhamnosus LPR and Bifidobacterium longum BL999) in Finnish infants
Study: 21979491
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in Finnish infants
Study: 21979491
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment in German infants
Study: 18926162
Drug: 10% glucose/insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glucose/insulin infusion
Study: 18926162
Drug: Intralipid plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid plus heparin infusion
Study: 12360590
Drug: CPAP-therapy (REMstar
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP-therapy (REMstar Choice, Respironics, USA)
Study: 2101170
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release naproxen (750 mg/day for 10-15 days)
Study: 2101170
Drug: Standard naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard naproxen (two 375 mg/day capsules for 10-15 days)
Study: 28564557
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg orally twice daily)
Study: 21848448
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type B (BTX‐B) injections on one side of the face
Study: 21848448
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control injections on the other side of the face
Study: 9144684
Drug: Paclitaxel (Taxol)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (Taxol) 175 mg/m2 followed by cisplatin 80 mg/m2
Study: 9144684
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 followed by teniposide (Vumon) 100 mg/m2
Study: 9316683
Drug: Nimodipine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (90 mg q.d.)
Study: 8494126
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg
Study: 3234468
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg with Diazepam 10 mg
Study: 28550377
Drug: Hydroxycellulose (HEC)
Normalized name: Hydroxycellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxycellulose (HEC) placebo gel
Study: 27871242
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy for 12 months
Study: 25183661
Drug: Methylphenidate modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate modified-release long-acting formulation (MPH-LA) at 20 mg/day, up-titrated to 40-80 mg/day
Study: 25183661
Drug: Methylphenidate modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate modified-release long-acting formulation (MPH-LA)
Study: 20808923
Drug: Amodiaquine &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine & Artesunate (AS+AQ) monthly
Study: 17511193
Drug: KY gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: KY gel
Study: 16014845
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (DEC/ALB)
Study: 10193779
Drug: TASP-V (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TASP-V (10 microg kg(‐1) intranasal pretreatment)
Study: 10193779
Drug: TASP-V (1.275
Approvals — FDA: no, EMA: no, PMDA: no
Description: TASP-V (1.275 microg kg(‐1) intranasal pretreatment)